Diabetes, fatty liver and obesity are well-known lifestyle-related diseases caused by poor diet, a lack of exercise and stress. One of the main problems here is the overloading of the fat tissue’s storage capacity, which leads to fat accumulation in the liver and muscles and, amongst other things, also promotes the development of type 2 diabetes. Researchers led by biochemist Rudolf Zechner at the University of Graz are working intensively on regulating the enzyme adipose triglyceride lipase (ATGL), which releases fatty acids into the blood. In a mouse model involving overweight mice, various inhibitors of this enzyme have already been successfully used to reduce fat breakdown in muscles and organs. This can prevent, or at least reduce, conditions such as obesity and diabetes. One of the causes of fatty liver is an elevated level of fatty acids in the blood. These subsequently enter tissues not intended for fat storage. Incidentally, they prevent the uptake of glucose into muscle and adipose tissue, which can lead to insulin resistance, a precursor to type 2 diabetes. In a further step, an active substance (Atglistatin NG-497) has now been developed which could also be suitable for use in humans. At least in cell culture models, the inhibitor demonstrates complete inhibition of ATGL. No harmful side effects were observed either. Further preliminary studies are now to follow before the new drug can be used in clinical trials involving humans. Reference: University of Graz, Small-Molecule Inhibitors Targeting Lipolysis in Human Adipocytes, J Am Chem Soc 2022, https://pubs.acs.org/doi/10.1021/jacs.1c10836
Enzyme inhibitors for diabetes and fatty liver disease